Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion OyjORINF 100 EV-to-EBITDA is 14.59 as of Jul. 27, 2026, which is 20% below its 10-year median of 18.33. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $77.19. The stock has 4 warning signs investors should review. Among 742 Drug Manufacturers companies, Orion Oyj ranks worse than 56.87% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Orion Oyj's enterprise value is $12,577 Mil.
Orion Oyj's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $862 Mil. Therefore, Orion Oyj's EV-to-EBITDA for today is 14.59.
The historical rank and industry rank for Orion Oyj's EV-to-EBITDA or its related term are showing as below:
ORINF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.65 Med: 18.33 Max: 27.79
Current: 14.93
During the past 13 years, the highest EV-to-EBITDA of Orion Oyj was 27.79. The lowest was 12.65. And the median was 18.33.
ORINF's EV-to-EBITDA is ranked worse than 56.87% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs ORINF: 14.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Orion Oyj (OTCPK:ORINF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Oyj's share price for today is $82.75.
Orion Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.856.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Orion Oyj's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Orion Oyj's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Oyj's EV-to-EBITDA falls into.
Orion Oyj's current Enterprise Value is $12,577 Mil.
Orion Oyj's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $862 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Oyj (ORINF) has a EV-to-EBITDA of 14.59 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Oyj. This is 20% below median its historical median of 18.33. Over the past decade, Orion Oyj's EV-to-EBITDA has ranged from 12.65 to 27.79. According to the industry distribution chart, Orion Oyj ranks #422 out of 742 companies in the Drug Manufacturers industry, placing it in the top 56.9%.
Is Orion Oyj's EV-to-EBITDA too high?
Orion Oyj's current EV-to-EBITDA of 14.59 is 20% below median its 10-year median of 18.33. Over the past 10 years, this metric has ranged from a low of 12.65 to a high of 27.79. The Drug Manufacturers industry median EV-to-EBITDA is 12.93. Orion Oyj's value of 14.59 is 12.8% above this industry median. Based on the distribution chart, Orion Oyj ranks #422 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #422 out of 742 companies for EV-to-EBITDA. This places Orion Oyj in the lower half of its industry. The industry median EV-to-EBITDA is 12.93. Orion Oyj's value of 14.59 is 12.8% above this benchmark. Historically, Orion Oyj's own EV-to-EBITDA has ranged from 12.65 to 27.79 over the past decade. While the company's 10-year median is 18.33 vs. the industry median of 12.93, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current EV-to-EBITDA of 14.59 is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Oyj. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current EV-to-EBITDA is 14.59, which is 20% below median its own 10-year median of 18.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current EV-to-EBITDA of 14.59. The stock's GF Value™ is $77.19, compared to a current price of $82.75 — trading 7.2% above its estimated fair value. The current EV-to-EBITDA is 14.59, which is 20% below median its 10-year median of 18.33 and 12.8% above the Drug Manufacturers industry median of 12.93. Orion Oyj's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Orion Oyj (ORINF), the current EV-to-EBITDA is 14.59 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 7.2% above its estimated GF Value™ of $77.19.
Key valuation signals for ORINF:
EV-to-EBITDA: 14.59 (20% below median its 10-year median of 18.33)
GF Value™: $77.19 vs. price of $82.75 (7.2% above fair value)
Industry Position: 12.8% above the Drug Manufacturers median (#422 of 742)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score
Get the complete analysis for ORINF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
